文献速递中医内科中药与中成药合理使用

中药治疗非酒精性脂肪性肝病的疗效与安全性:随机对照试验的系统综述

Efficacy and safety of traditional Chinese medicines for non-alcoholic fatty liver disease: a systematic literature review of randomized controlled trials.
PubMed 文献 · Chin Med · 2021-01-11

本研究系统检索6个数据库至2020年9月,纳入53项随机对照试验共5997例非酒精性脂肪性肝病患者,评估中药的疗效与安全性。结果显示中药可能改善中医证候积分、肝功能及血脂,但报告质量普遍较差、偏倚风险多不确定,无法得出确切结论。

要点

  • 中药可能改善NAFLD患者中医证候积分、肝功能及血脂。
  • 报告质量普遍较差,偏倚风险多不确定,无法得出确切疗效安全性结论。
  • 建议改进RCT方案、扩大样本、多中心并聚焦特定中药以产出高质量证据。

核心结论

  • 有部分RCT证据支持中药治疗NAFLD的有效性和安全性,但因RCT质量存疑无法做出确切推荐。

研究设计与样本

  • 系统检索PubMed、Cochrane Library、EMBASE、Web of Science、Scopus及中国知网自建库至2020年9月的随机对照试验。
  • 纳入53项RCT共5997例NAFLD患者,每项RCT测试一种不同中药,共涉及53种中药。
  • 纳入比较中药与不治疗、安慰剂、非药物和/或药物干预的RCT,不限语言或盲法。
  • 采用CONSORT-CHM评估报告质量,采用Cochrane偏倚风险工具评估每项研究的偏倚风险。

主要发现

  • 基于RCT结果评估,中药可能具有改善中医证候积分、肝功能及血脂谱等多种有益效应。
  • 报告了与中药使用相关的一系列非严重、可逆的不良反应。
  • 无法就中药治疗NAFLD的疗效和安全性得出结论。
  • 所有试验的报告质量普遍较差,偏倚风险大多不确定。

临床怎么用

  • 临床可考虑中药作为NAFLD的辅助管理选项,但需向患者说明证据质量有限且存在非严重可逆不良反应。
  • 应用中药时需监测中医证候积分、肝功能及血脂谱变化。

局限性

  • 纳入RCT的报告质量普遍较差。
  • 所有试验的偏倚风险大多不确定。
  • 每项RCT测试不同中药,共53种,难以汇总特定中药的疗效安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease that may progress into, in the absence of proper treatment, severe liver damage. While the optimal pharmacotherapy for NAFLD remains uncertain and the adherence to lifestyle interventions is challenging, the use of herbal medicines such as traditional Chinese medicines (TCMs) to manage the condition is common. The evidence about TCMs in the management of NAFLD is continuously developing through randomized controlled trials (RCTs). This study aims to identify and evaluate the emerging evidence about the efficacy and safety of TCMs for NAFLD. METHODS: A systematic literature search was conducted to identify RCTs which investigated TCMs in the management of NAFLD published in 6 electronic databases including PubMed, the Cochrane Library, EMBASE, Web of Science, Scopus and China National Knowledge Infrastructure since inception to September 2020. RCTs comparing TCMs with no treatment, placebo, non-pharmacological and/or pharmacological interventions were included irrespective of language or blinding. The quality of reporting was evaluated using the Consolidated Standards of Reporting Trials Statement extensions for Chinese herbal medicine Formulas (CONSORT-CHM). Risk-of-bias for each study was assessed using the Cochrane risk of bias tool. RESULTS: A total of 53 RCTs involving 5997 participants with NAFLD were included in this review. Each included RCT tested a different TCMs giving a total of 53 TCMs identified in this study. Based on the evaluation of the RCT results, TCMs might have various beneficial effects such as improving TCM syndrome score, liver function, and body lipid profile. A range of non-serious, reversible adverse effects associated with the use of TCMs were also reported. However, no conclusion about the efficacy and safety of TCMs in NAFLD can be made. The quality of reporting was generally poor and the risks of bias was mostly uncertain in all trials. CONCLUSIONS: There is some evidence from RCTs that supported the effectiveness and safety of TCMs for NAFLD. However, no conclusive recommendations can be made due to the questionable quality of the RCTs. Improvement in the RCT protocol, the use of a larger sample size, a setting of multicenter, and a more focused approach in selecting TCMs are recommended for developing high quality evidence about the use of TCMs in managing NAFLD.

来源:Chin Med,查看原文。版权归原作者所有。

引用

  1. Liang Z, Chen X, Shi J, et al. Efficacy and safety of traditional Chinese medicines for non-alcoholic fatty liver disease: a systematic literature review of randomized controlled trials. Chin Med. 2021. PMID: 33430929. doi:10.1186/s13020-020-00422-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。